Standard Dosing Schedule for Skyrizi in Plaque Psoriasis
Skyrizi (risankizumab-rzaa) is injected subcutaneously every 12 weeks after an initial loading phase. Start with two 150 mg doses (one in each thigh or abdomen) at weeks 0 and 4, then 150 mg every 12 weeks thereafter.[1]
How Long Until Maintenance Doses?
The first two doses space 4 weeks apart to build drug levels quickly. From week 12 onward, injections occur every 3 months, aligning with typical clinical trial regimens for moderate-to-severe plaque psoriasis in adults.[1][2]
What If I Miss a Dose?
Inject as soon as possible if within 12 weeks of the scheduled time. Resume the every-12-week schedule from there. Consult a doctor if more than 12 weeks have passed.[1]
Dosage for Other Conditions
For psoriatic arthritis, the schedule matches plaque psoriasis. Crohn's disease uses induction (weeks 0, 4, 8) followed by 180 mg every 8 weeks. Ulcerative colitis induction is 600 mg IV (across three infusions), then 180 mg subcutaneous every 8 weeks.[1][2]
Injection Tips and Sites
Use prefilled syringes or on-body injectors for 150 mg. Rotate sites: upper thighs, abdomen (avoid 2 inches around navel), upper arms (with help). Full dose takes 75 seconds per site.[1]
Who Makes Skyrizi and Common Patient Questions
AbbVie manufactures Skyrizi. Patients often ask about needle phobia—training resources are available. No generic or biosimilar yet; U.S. patents extend into the 2030s.[1][3]
[1]: Skyrizi Prescribing Information, AbbVie, https://www.skyrizi.com/content/dam/skyrizi/pdfs/SKYRIZI-PI.pdf
[2]: FDA Approval Summary, Skyrizi for Plaque Psoriasis, https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761061s000lbl.pdf
[3]: DrugPatentWatch.com, Skyrizi Patents, https://www.drugpatentwatch.com/p/tradename/SKYRIZI